nach oben

Irish Journal of Medical Science (1971 -)

Erschienen in:

Open Access 14.02.2023 | Original Article

Occurrence rates and risk factors of in-hospital venous thromboembolism, major bleeding, and death in patients receiving fondaparinux after orthopedic surgery or trauma surgery

verfasst von: Ya Ding, Bowen Han, Bin Yuan, Mingjun Nie, Renyang Liu, Ming Zhao, Hongliang Wang

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 6/2023

Abstract

Aim

Fondaparinux is a synthetic anticoagulant that inhibits thrombosis by suppressing factor Xa. The efficacy of fondaparinux for orthopedic surgeries has been revealed by several foreign studies; however, relevant evidence in Chinese patients is lacking. This study intended to investigate the occurrence rate and risk factors of in-hospital venous thromboembolism (VTE), major bleeding, and death in patients receiving fondaparinux after orthopedic surgery or trauma surgery.

Methods

Totally, 1258 patients who received fondaparinux after orthopedic surgery or trauma surgery were retrospectively enrolled. Meanwhile, in-hospital VTE, major bleeding, and death were obtained for assessment. Besides, adverse events were recorded.

Results

The occurrence rates of in-hospital VTE, major bleeding, and death were 2.5%, 21.8%, and 0.0%, respectively. The multivariate logistic regression analysis revealed that only age (> 60 years vs. ≤ 60 years) (odd ratios (OR) = 3.380, P = 0.013) was independently correlated with increased risk of in-hospital VTE. Additionally, osteoarthritis diagnosis (OR = 3.826, P < 0.001), femoral head necrosis diagnosis (OR = 1.809, P = 0.034), hip replacement (vs. internal fracture fixation) (OR = 2.199, P = 0.007), knee replacement (vs. internal fracture fixation) (OR = 2.781, P = 0.002), and serum creatinine (abnormal vs. normal) (OR = 1.677, P = 0.012) were independently linked to a higher risk of in-hospital major bleeding. Moreover, the common adverse events included pain (56.6%), wound bleeding (23.0%), increased drainage (5.2%), etc.

Conclusion

Fondaparinux realizes low occurrence rates of in-hospital VTE and major bleeding with tolerable adverse events in patients receiving orthopedic surgery or trauma surgery.

Supplementary file1 (TIF 1272 kb)

Supplementary file2 (TIF 2294 kb)

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s11845-023-03289-7.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Orthopedic surgery or trauma surgery is a surgical branch that focuses on the conditions involved in the musculoskeletal system (such as bones, joints, tendons, and ligaments) [1]. Some of the commonly performed orthopedic surgeries or trauma surgeries include hip replacement, knee replacement, meniscus repair, and internal fracture fixation [2‐4]. Notably, patients undergoing orthopedic surgery or trauma surgery are often at high risk of venous thromboembolism (VTE), which is a major cause of postoperative disability and death [5‐7]; in this case, anticoagulants (such as unfractionated heparin, enoxaparin, and dabigatran) are required to relieve this situation [8]. However, major bleeding is very likely to occur after receiving the anticoagulants, which also seriously affects the patient’s postoperative recovery and even carries the risk of death [9‐11]. Therefore, it is crucial to investigate feasible and safe anticoagulants, which balance the occurrence of VTE and major bleeding for patients after receiving orthopedic surgery or trauma surgery.

Fondaparinux specifically binds to the activation site of antithrombin (AT) to accelerate factor Xa complex formation approximately by 300 folds, leading to rapid inhibition of factor Xa, which in turn reduces thrombin production; meanwhile, at a certain concentration, fondaparinux also forms a stable complex with platelet factor 4 (PF4) to enhance palate aggregation and activation [12, 13]. Clinically, fondaparinux is applied to prevent VTE in patients undergoing orthopedic surgery or trauma surgery [14‐17]. For instance, a previous study claims that fondaparinux is effective in preventing VTE with an occurrence rate of 1.0% in patients receiving major orthopedic surgery [15]. Meanwhile, a double-arm study reveals that the risk of VTE is 6% in patients receiving fondaparinux and 8% in patients receiving enoxaparin after hip replacement surgery [16]. Moreover, fondaparinux (8.3%) obviously reduces the incidence of VTE compared with enoxaparin (19.1%) in patients receiving hip-fracture surgery [18]. However, the above-mentioned studies are carried out in countries other than China [15, 16, 18]. In addition, fondaparinux has just been launched in China recently; therefore, relevant evidence regarding fondaparinux in Chinese patients receiving orthopedic surgery or trauma surgery is scarce.

Accordingly, this multi-center, single-arm, retrospective study intended to explore the occurrence rates of in-hospital VTE, major bleeding, and death as well as their risk factors in Chinese patients receiving fondaparinux after orthopedic surgery or trauma surgery.

Materials and methods

Patients

This was a multi-center, single-arm, retrospective study, which reviewed 1258 patients who received fondaparinux after orthopedic surgery or trauma surgery from March 2020 to October 2022. The screened criteria contained the following: (i) aged over 18 years old, (ii) underwent orthopedic surgery or trauma surgery, and (ii) received fondaparinux for anticoagulation prophylaxis. The exclusion criteria were as follows: (i) diagnosis of deep venous thrombosis at admission (except for intramuscular venous thrombosis); (ii) had a history of anticoagulant drugs before inclusion; (iii) underwent total hip or total knee replacement over 2 times; (iv) underwent orthopedic surgery, trauma surgery, spinal surgery, ophthalmic surgery, or brain surgery within 3 months prior to admission; (v) had a history of active bleeding, gastrointestinal ulcer, vasoproliferative gastrointestinal disease, hemorrhagic stroke, or congenital or acquired bleeding disorder; (vi) had a history of acute bacterial endocarditis; (vii) had a cardiac failure of stages II–III; and (viii) had severe renal impairment (creatinine clearance rate ≤ 20 mL/min). This study had been approved by the Ethics Committee. Written informed consent was obtained from each patient.

Medication

The administration of fondaparinux was started at 6–24 h after surgery at the dose of 2.5 mg/day by subcutaneous injection [19]. For patients with a Caprini score ≥ 2 and elective surgery, fondaparinux was administered at admission and discontinued at 24 h before surgery. Antiplatelet drugs such as aspirin and indobufen could be added for appropriate patients according to the disease status and medical advice.

Data collection

Clinical characteristics of patients were gained, which included age, gender, history of drink, history of smoke, diagnosis, Caprini score, surgery type, medication, serum creatinine, creatinine clearance rate, and platelet count. Besides, venous thromboembolism (VTE), major bleeding, and death in hospital were obtained for assessment. VTE contained symptomatic pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), asymptomatic DVT, distal DVT, and proximal DVT. Major bleeding was assessed per the International Society on Thrombosis and Haemostasis (ISTH) guideline, which contained fatal bleeding, significant bleeding (hemoglobin declined ≥ 2 g/dL, or leading to the transfusion of red blood cells in whole blood more than two units), and bleeding at critical position (retroperitoneal, intracranial, spinal, intraocular, joint space, pericardial, compartment syndrome, etc.) [20]. Additionally, adverse events were also recorded.

Statistics

SPSS v26.0 (IBM Corp., America) was utilized for analysis. GraphPad Prism v9.0 (GraphPad Software Inc., America) was utilized for figure plotting. Comparison analysis was performed using chi-square test or Fisher’s exact test. Factors related to VTE and major bleeding in hospital were screened using univariate and forward stepwise multivariate logistic regression analyses. P < 0.05 was considered significant.

Results

Clinical properties

The included patients who received fondaparinux after orthopedic surgery or trauma surgery had a mean age of 63.6 ± 13.7 years with 740 (58.8%) females and 518 (41.2%) males. Meanwhile, the median (interquartile range (IQR)) of the Caprini score was 10.0 (9.0–11.0). In terms of surgery type, 336 (26.7%) patients received internal fracture fixation, 352 (28.0%) patients received hip replacement, 430 (34.2%) patients received knee replacement, and 140 (11.1%) received other surgeries. In addition, 78 (6.2%) patients received antiplatelet drugs, including 33 (2.6%) patients who applied aspirin, 41 (3.3%) who administered indobufen, and 4 (0.3%) patients who used other antiplatelet drugs. Moreover, the median (IQR) values of serum creatinine, creatinine clearance rate, and platelet count were 59.6 (51.0–71.0) μmol/L, 92.3 (72.3–116.9) mL/min, and 209.0 (168.0–259.0) 10⁹/L, respectively. The specific information is listed in Table 1.

Table 1

Clinical characteristics

Items	Patients (N = 1258)
Age (years), mean ± SD	63.6 ± 13.7
Gender, no. (%)
Female	740 (58.8)
Male	518 (41.2)
History of drink, no. (%)	117 (9.3)
History of smoke, no. (%)	129 (10.3)
Diagnosis, no. (%)
Osteoarthritis	479 (38.1)
Fracture of hip	292 (23.2)
Femoral head necrosis	132 (10.5)
Fracture around knee joint	118 (9.4)
Fracture of distal knee joint	105 (8.3)
Fracture of femoral	75 (6.0)
Others	210 (16.7)
Caprini score, median (IQR)	10.0 (9.0–11.0)
Surgery type, no. (%)
Internal fracture fixation	336 (26.7)
Hip replacement	352 (28.0)
Knee replacement	430 (34.2)
Others	140 (11.1)
Antiplatelet drugs, no. (%)	78 (6.2)
Aspirin	33 (2.6)
Indobufen	41 (3.3)
Others	4 (0.3)
Serum creatinine (μmol/L), median (IQR)	59.6 (51.0–71.0)
Creatinine clearance rate (mL/min), median (IQR)	92.3 (72.3–116.9)
Platelet count (10⁹/L), median (IQR)	209.0 (168.0–259.0)

SD standard deviation, IQR interquartile range

Occurrence rates of in-hospital VTE, major bleeding, and death

The occurrence rate of in-hospital VTE was 2.5% (Fig. 1A); meanwhile, the occurrence rate of in-hospital major bleeding was 21.8% (Fig. 1B); notably, no (0.0%) in-hospital death (Fig. 1C) occurred in patients receiving fondaparinux after orthopedic surgery or trauma surgery.

Independent factors for in-hospital VTE

According to univariate logistic regression analysis, age (> 60 years vs. ≤ 60 years) (odds ratio (OR) = 3.406, P = 0.012) was related to higher risk of in-hospital VTE, whereas gender, history of drinking, history of smoking, diagnosis, surgery type, etc. (all P > 0.05), were not associated with the occurrence of in-hospital VTE in patients receiving fondaparinux after orthopedic surgery or trauma surgery (Fig. 2A).

Further forward stepwise multivariate logistic regression analysis suggested that only age (> 60 years vs. ≤ 60 years) (OR = 3.380, P = 0.013) was independently correlated with increased risk of in-hospital VTE in patients receiving fondaparinux after orthopedic surgery or trauma surgery (Fig. 2B).

Independent factors for in-hospital major bleeding

Univariate logistic regression analysis revealed that osteoarthritis (yes vs. no) (OR = 5.686, P < 0.001), hip replacement (vs. internal fracture fixation) (OR = 3.438, P < 0.001), knee replacement (vs. internal fracture fixation) (OR = 8.473, P < 0.001), and serum creatinine (abnormal vs. normal) (OR = 1.544, P = 0.017) were correlated with increased risk of in-hospital major bleeding, while fracture of hip (yes vs. no) (OR = 0.368, P < 0.001), fracture around knee joint (yes vs. no) (OR = 0.143, P < 0.001), fracture of distal knee joint (yes vs. no) (OR = 0.130, P < 0.001), fracture of femoral (yes vs. no) (OR = 0.472, P = 0.038), and other antiplatelet drugs (yes vs. no) (OR = 0.290, P < 0.001) were related to decreased risk of in-hospital major bleeding in patients receiving fondaparinux after orthopedic surgery or trauma surgery (Fig. 3A).

Further forward stepwise multivariate logistic regression analysis disclosed that osteoarthritis (yes vs. no) (OR = 3.826, P < 0.001), femoral head necrosis (OR = 1.809, P = 0.034), hip replacement (vs. internal fracture fixation) (OR = 2.199, P = 0.007), knee replacement (vs. internal fracture fixation) (OR = 2.781, P = 0.002), and serum creatinine (abnormal vs. normal) (OR = 1.677, P = 0.012) were independently linked with a higher risk of in-hospital major bleeding in patients receiving fondaparinux after orthopedic surgery or trauma surgery (Fig. 3B).

Adverse events

In terms of adverse events, 750 (59.6%) patients suffered from surgical complications, including 712 (56.6%) patients with pain, 289 (23.0%) patients with wound bleeding, 66 (5.2%) patients with increased drainage, 15 (1.2%) patients with infection, and 245 (19.5%) patients with others. Meanwhile, 5 (0.4%) patients had adverse reactions at the injection site, and 138 (11.0%) patients had other adverse events (Table 2).

Table 2

Adverse events

Adverse events	Patients (N = 1258)
Surgical complications, no. (%)	750 (59.6)
Pain	712 (56.6)
Wound bleeding	289 (23.0)
Increased drainage	66 (5.2)
Infection	15 (1.2)
Others	245 (19.5)
Adverse reactions at injection site, no. (%)	5 (0.4)
Other adverse events, no. (%)	138 (11.0)

Subgroup analysis of in-hospital VTE and major bleeding comparison based on different surgeries

The occurrence rates of in-hospital VTE were not different among patients receiving internal fracture fixation, hip replacement, knee replacement, and other surgeries (P = 0.681). In addition, the occurrence rate of in-hospital major bleeding was highest in patients receiving knee replacement, followed by patients receiving hip replacement and internal fracture fixation, and lowest in patients receiving other surgeries (P < 0.001) (Supplementary Fig. 1).

Subgroup analysis of in-hospital VTE comparison based on different diagnoses

In-hospital VTE rates were not different between patients diagnosed with osteoarthritis and those who did not (P = 0.949), between patients diagnosed with fracture of hip and those who did not (P = 0.052), between patients diagnosed with femoral head necrosis and those who did not (P = 0.569), between patients diagnosed with fracture around knee joint and those who did not (P = 1.000), between patients diagnosed with fracture of distal knee joint and those who did not (P = 1.000), between patients diagnosed with fracture of femoral and those who did not (P = 1.000), and between patients diagnosed with others and those who did not (P = 0.109) (Supplementary Fig. 2).

Discussion

Fondaparinux is a factor Xa inhibitor, which has been applied to prevent VTE in various patients, including patients receiving orthopedic surgery or trauma surgery [14, 17, 21‐24]. For example, a study conducted in Europe reports that fondaparinux (4%) exerts a better effect in preventing VTE occurrence compared to enoxaparin (9%) in patients receiving hip replacement surgery [25]. In addition, a study performed in America claims that fondaparinux (1.5%) effectively reduces the occurrence rate of VTE compared to dalteparin (2.1%), enoxaparin (2.3%), and unfractionated heparin (4.2%) in patients receiving orthopedic surgery; meanwhile, the occurrence rate of bleeding is lower in patients receiving fondaparinux (1.5%) compared to patients receiving unfractionated heparin (25%) [26]. Moreover, a previous study carried out in America reveals that the occurrence rate of VTE is lower in patients receiving fondaparinux (12.5%) compared to those receiving enoxaparin (27.8%) [17]. However, since fondaparinux is just released in China lately, relevant evidence regarding the effect of fondaparinux in Chinese patients is still limited. The current study discovered that the occurrence rate of in-hospital VTE, major bleeding, and death was 2.5%, 21.8%, and 0.0% in patients receiving orthopedic surgery or trauma surgery, which was in line with other studies (mentioned above) [25, 26]. It turned out that fondaparinux is effective in Chinese patients receiving orthopedic surgery or trauma surgery. The possible explanations would be that (1) fondaparinux could bind to antithrombin, leading to rapid inhibition of factor Xa, which affected the course of the coagulation cascade reaction, thereby suppressing thrombin formation and thrombus enlargement [27], and (2) fondaparinux formed a stable complex with PF4, which could enhance platelet aggregation and activation, thus resulting in a low incidence of major bleeding events [13].

Meanwhile, the current study also found that age > 60 years was a strong risk factor for the occurrence of in-hospital VTE in patients receiving fondaparinux after orthopedic surgery or trauma surgery. A possible explanation would be that older patients (age > 60 years) had higher hemoconcentration and therefore more likely to have in-hospital VTE. Apart from that, this study also discovered that osteoarthritis, femoral head necrosis, hip replacement, and knee replacement were independently linked to a higher risk of in-hospital major bleeding in patients receiving fondaparinux after orthopedic surgery or trauma surgery. The potential reason would be that osteoarthritis and femoral head necrosis could cause intraarticular bleeding, while hip replacement and knee replacement would directly damage the blood vessels near the bone, which further contributed to the major bleeding [28‐30]. Besides, abnormal serum creatinine was also an independent risk factor for in-hospital major bleeding. It could be explained by that the abnormal serum creatinine represented dysfunction of the kidney, which contributed to the decrease in platelet counts [31]. Therefore, abnormal serum creatinine was correlated with increased in-hospital major bleeding risk.

Moreover, rare studies report adverse events in patients receiving fondaparinux after orthopedic surgery or trauma surgery [16, 32]. The current study discovered that the most common adverse events that occurred in patients receiving fondaparinux after orthopedic surgery or trauma surgery were surgical complications (59.6%) (including pain, wound bleeding, increased drainage, and infection), adverse reactions at injection site (0.4%), and other adverse events (11.0%). Notably, most of the adverse events were manageable and tolerable, indicating that fondaparinux had a good safety profile for patients receiving orthopedic surgery or trauma surgery.

Notably, several limitations should be noticed: (1) although 1258 patients were enrolled in this study, the administration of anticoagulants for orthopedic surgery or trauma surgery was quite prevalent and general. Therefore, the base of patients using anticoagulants would be large, indicating that the sample size could be further expanded; (2) this was not a comparative study; thus, a double-arm study was warranted to compare the efficacy of fondaparinux with other anticoagulants (such as unfractionated heparin, enoxaparin, and dabigatran) in patients receiving orthopedic surgery or trauma surgery; and (3) this study only explored the occurrence rate of in-hospital VTE, major bleeding, and death; thus, the long-term effect of fondaparinux in patients receiving orthopedic surgery or trauma surgery still needed exploration.

In summary, fondaparinux achieves low occurrence rates of in-hospital VTE and major bleeding with a good safety profile in patients receiving orthopedic surgery or trauma surgery. However, further validation is still required.

Declarations

Not applicable.

Competing interests

The authors declare no competing interests.

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt testen ¹

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Jetzt testen ²

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (TIF 1272 kb)

Supplementary file2 (TIF 2294 kb)

Akhter S, Mundi R, Bhandari M (2020) The impact of evidence in surgery of the musculoskeletal system. World J Surg 44(4):1020–1025. https://doi.org/10.1007/s00268-019-04955-7CrossRefPubMed

Karachalios TS, Koutalos AA, Komnos GA (2020) Total hip arthroplasty in patients with osteoporosis. Hip Int 30(4):370–379. https://doi.org/10.1177/1120700019883244CrossRefPubMed

McClain WD, DeFoor MT, Patzkowski JC (2021) meniscus repair techniques. Sports Med Arthrosc Rev 29(3):e34–e43. https://doi.org/10.1097/JSA.0000000000000320CrossRefPubMed

Demirel M, Polat G, Ersen A et al (2021) Internal fixation for osteochondritis dissecans lesions of the knee in patients with physeal closure. Acta Orthop Traumatol Turc 55(3):201–207. https://doi.org/10.5152/j.aott.2021.19307CrossRefPubMedPubMedCentral

Majima T, Oshima Y (2021) Venous thromboembolism in major orthopedic surgery. J Nippon Med Sch 88(4):268–272. https://doi.org/10.1272/jnms.JNMS.2021_88-418CrossRefPubMed

Zambelli R, Nemeth B, Touw CE et al (2021) High risk of venous thromboembolism after orthopedic surgery in patients with thrombophilia. J Thromb Haemost 19(2):444–451. https://doi.org/10.1111/jth.15163CrossRefPubMed

Khan F, Tritschler T, Kahn SR, Rodger MA (2021) Venous thromboembolism. Lancet 398(10294):64–77. https://doi.org/10.1016/S0140-6736(20)32658-1CrossRefPubMed

Falck-Ytter Y, Francis CW, Johanson NA et al (2012) Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e278S-e325S. https://doi.org/10.1378/chest.11-2404CrossRefPubMedPubMedCentral

Milling TJ Jr, Ziebell CM (2020) A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery. Trends Cardiovasc Med 30(2):86–90. https://doi.org/10.1016/j.tcm.2019.03.004CrossRefPubMed

10.

Gomez-Outes A, Alcubilla P, Calvo-Rojas G et al (2021) Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants. J Am Coll Cardiol 77(24):2987–3001. https://doi.org/10.1016/j.jacc.2021.04.061CrossRefPubMed

11.

Kleiboer B, Layer MA, Cafuir LA et al (2022) Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: a prospective multicenter observational study. J Thromb Haemost 20(4):857–865. https://doi.org/10.1111/jth.15654CrossRefPubMedPubMedCentral

12.

Zhang Y, Zhang M, Tan L et al (2019) The clinical use of fondaparinux: a synthetic heparin pentasaccharide. Prog Mol Biol Transl Sci 163:41–53. https://doi.org/10.1016/bs.pmbts.2019.02.004CrossRefPubMed

13.

Chen LY, Khan N, Lindenbauer A, Nguyen TH (2022) When will fondaparinux induce thrombocytopenia? Bioconjug Chem 33(8):1574–1583. https://doi.org/10.1021/acs.bioconjchem.2c00316CrossRefPubMedPubMedCentral

14.

Fu D, Li L, Li Y et al (2022) Fondaparinux sodium and low molecular weight heparin for venous thromboembolism prophylaxis in Chinese patients with major orthopedic surgery or trauma: a real-world study. BMC Surg 22(1):243. https://doi.org/10.1186/s12893-022-01652-6CrossRefPubMedPubMedCentral

15.

Singelyn FJ, Verheyen CC, Piovella F et al (2007) The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the EXPERT Study. Anesth Analg 105(6):1540–1547. https://doi.org/10.1213/01.ane.0000287677.95626.60CrossRefPubMed

16.

Turpie AG, Bauer KA, Eriksson BI et al (2002) Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 359(9319):1721–1726. https://doi.org/10.1016/S0140-6736(02)08648-8CrossRefPubMed

17.

Bauer KA, Eriksson BI, Lassen MR et al (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 345(18):1305–1310. https://doi.org/10.1056/NEJMoa011099CrossRefPubMed

18.

Eriksson BI, Bauer KA, Lassen MR et al (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 345(18):1298–1304. https://doi.org/10.1056/NEJMoa011100CrossRefPubMed

19.

Kim KI, Kim GB, Lee MG, Song SJ (2021) Do we need chemoprophylaxis to prevent venous thromboembolism following medial open-wedge high tibial osteotomy? J Knee Surg 34(9):1007–1013. https://doi.org/10.1055/s-0039-1700976CrossRefPubMed

20.

Farge D, Frere C, Connors JM et al (2019) 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 20(10):e566–e581. https://doi.org/10.1016/S1470-2045(19)30336-5CrossRefPubMed

21.

He T, Han F, Wang J et al (2021) Efficacy and safety of anticoagulants for postoperative thrombophylaxis in total hip and knee arthroplasty: a PRISMA-compliant Bayesian network meta-analysis. PLoS ONE 16(6):e0250096. https://doi.org/10.1371/journal.pone.0250096CrossRefPubMedPubMedCentral

22.

Kolluri R, Plessa AL, Sanders MC et al (2016) A randomized study of the safety and efficacy of fondaparinux versus placebo in the prevention of venous thromboembolism after coronary artery bypass graft surgery. Am Heart J 171(1):1–6. https://doi.org/10.1016/j.ahj.2015.10.013CrossRefPubMed

23.

Tokuhara K, Matsushima H, Ueyama Y et al (2017) Efficacy and safety of thromboembolism prophylaxis with fondaparinux in Japanese colorectal cancer patients undergoing laparoscopic surgery: a phase II study. Int J Surg 42:203–208. https://doi.org/10.1016/j.ijsu.2017.04.014CrossRefPubMed

24.

Senzolo M, Piano S, Shalaby S et al (2021) Comparison of fondaparinux and low-molecular-weight heparin in the treatment of portal vein thrombosis in cirrhosis. Am J Med 134(10):1278-1285.e1272. https://doi.org/10.1016/j.amjmed.2021.05.013CrossRefPubMed

25.

Lassen MR, Bauer KA, Eriksson BI et al (2002) Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359(9319):1715–1720. https://doi.org/10.1016/S0140-6736(02)08652-XCrossRefPubMed

26.

Shorr AF, Kwong LM, Sarnes M et al (2007) Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis. Thromb Res 121(1):17–24. https://doi.org/10.1016/j.thromres.2007.02.013CrossRefPubMed

27.

Zhou Z, Zhang L, Wu X et al (2022) Chemical synthesis and pharmacological properties of heparin pentasaccharide analogues. Eur J Med Chem 234:114256. https://doi.org/10.1016/j.ejmech.2022.114256CrossRefPubMed

28.

Lotz MK, Kraus VB (2010) New developments in osteoarthritis. Posttraumatic osteoarthritis: pathogenesis and pharmacological treatment options. Arthritis Res Ther 12(3):211. https://doi.org/10.1186/ar3046CrossRefPubMedPubMedCentral

29.

Beck M, Siebenrock KA, Affolter B et al (2004) Increased intraarticular pressure reduces blood flow to the femoral head. Clin Orthop Relat Res 424:149–152. https://doi.org/10.1097/01.blo.0000128296.28666.35CrossRef

30.

Oberweis BS, Nukala S, Rosenberg A et al (2013) Thrombotic and bleeding complications after orthopedic surgery. Am Heart J 165(3):427-433.e421. https://doi.org/10.1016/j.ahj.2012.11.005CrossRefPubMedPubMedCentral

31.

Boccardo P, Remuzzi G, Galbusera M (2004) Platelet dysfunction in renal failure. Semin Thromb Hemost 30(5):579–589. https://doi.org/10.1055/s-2004-835678CrossRefPubMed

32.

Tran AH, Lee G (2003) Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery. Ann Pharmacother 37(11):1632–1643. https://doi.org/10.1345/aph.1C104CrossRefPubMed

Titel: Occurrence rates and risk factors of in-hospital venous thromboembolism, major bleeding, and death in patients receiving fondaparinux after orthopedic surgery or trauma surgery
verfasst von: Ya Ding
Bowen Han
Bin Yuan
Mingjun Nie
Renyang Liu
Ming Zhao
Hongliang Wang
Publikationsdatum: 14.02.2023
Verlag: Springer International Publishing
Erschienen in: Irish Journal of Medical Science (1971 -) / Ausgabe 6/2023
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-023-03289-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Aim

Methods

Results

Conclusion

Supplementary Information

Publisher's Note

Introduction

Materials and methods

Patients

Medication

Data collection

Statistics

Results

Clinical properties

Occurrence rates of in-hospital VTE, major bleeding, and death

Independent factors for in-hospital VTE

Independent factors for in-hospital major bleeding

Adverse events

Subgroup analysis of in-hospital VTE and major bleeding comparison based on different surgeries

Subgroup analysis of in-hospital VTE comparison based on different diagnoses

Discussion

Declarations

Ethics approval and consent to participate

Consent for publication

Competing interests

Publisher's Note

Unsere Produktempfehlungen

e.Med Interdisziplinär

e.Med Innere Medizin

Supplementary Information

Weitere Artikel der Ausgabe 6/2023

Characteristics of potential concussive events in elite hurling: a video-analysis study

An audit of secondary prevention for peripheral arterial disease in primary care — scope for improved collaboration between vascular surgery and general practitioners

The risk of mortality and severe illness in patients infected with the omicron variant relative to delta variant of SARS-CoV-2: a systematic review and meta-analysis

Liraglutide combined with metformin treatment for obese people with type 2 diabetes mellitus: a systematic review and meta-analysis

Adherence of patients with age-related macular degeneration to AREDS 2-recommended nutritional supplements

“The best of a bad situation?” A mixed methods survey exploring patients’ perspectives on physiotherapy-led online group exercise programmes

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

Update Innere Medizin